SCHEMBL6477875

SCHEMBL6477875

CC(C)(C)OC(=O)C1[C@H]2CN(c3ccc(NC(=O)OCc4ccccc4)cc3F)C[C@@H]12

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 6/20 0.46
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
MGLL Q99685 3/20 0.42
NPY2R P49146 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM1A O60341 2/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
RCOR1 Q9UKL0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478512 0.90 RORC (0.45) RORCMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6477484 0.89 RORC (0.51) RORCMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6477625 0.85 KDM1A (0.47) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5464908 0.85 RORC (0.44) RORCMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6715302 0.85 RORC (0.44) RORCMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL6338415 0.82 MAPT (0.45) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6510132 0.82 NPY2R (0.52) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6340185 0.82 PTGDR2 (0.46) RORCMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL7810712 0.82 MAPT (0.48) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6209181 0.81 KDM1A (0.50) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875784-B2 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-04-05 US disclosed
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives PHARMACIA & UPJOHN COMPANY 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127530-A1 Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives OXA1L, CYP1B1, MT-CO1 RORC 339/4885MAPT 2671/4885NPC1 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.